§ Helen JonesTo ask the Secretary of State for Health what guidance his Department has given to NHS trusts on the use of Taxol combination treatments in the treatment of ovarian cancer. [34599]
§ Mr. BoatengTaxol is a drug licensed by the Medicines Control Agency for use in treating widespread cancer of the ovary or metastatic breast cancer where standard treatment regimes have failed. A clinical trial for first-line treatment of widespread breast cancer by Taxol in combination with other drugs is currently in progress. As with any other drug, it is a matter for individual clinicians, in discussion with their patients, to recommend a treatment regime which will be best for their patients. Guidance on clinical management of ovarian cancer was produced by the Standing Medical Advisory Committee and was published in November 1991.
§ Helen JonesTo ask the Secretary of State for Health how many women in the Warrington North constituency were diagnosed as having ovarian cancer in each of the years 1992 to 1997. [34600]
§ Mr. BoatengFigures for Warrington North are not available separately. The latest available data for Warrington residents are set out in the tables, and relate to the five-year period 1990–1994:
592W
Warrington residents 1990–1994: number of ovarian tumours Age Number 0–4 — 5–9 — 10–14 — 15–19 — 20–24 — 25–29 — 30–34 — 35–39 1 40–44 5 45–49 6
Warrington residents 1990–1994: number of ovarian tumours Age Number 50–54 12 55–59 12 60–64 7 65–69 14 70–74 12 75–79 14 80–84 4 85 plus 4 all ages 91
Warrington residents 1990–1994: age specific incidence rates per 100,000 Age Rate 0–4 — 5–9 — 10–14 — 15–19 — 20–24 — 25–29 — 30–34 — 35–39 3.2 40–44 15.2 45–49 19.4 50–54 44.3 55–59 51.0 60–64 31.2 65–69 65.9 70–74 61.3 75–79 89.2 80–84 35.0 85 plus 44.0 all ages 19.3 Source
Merseyside and Cheshire Cancer Registry, March 1998.